Vertex Pharmaceuticals | VRTX - Zinsaufwendungen Für Schuld

Aktienkurs
430.29
Täglich Wechseln
-4.81 -1.11%
Monatlich
-5.42%
Jährlich
-12.87%
Q2 Prognose
421.08




Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 740M 40M 2025-06
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
Arrowhead Research USD 22.5M 811K 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Gilead Sciences USD 255M 1000K 2025-12
Incyte USD 582K 10K 2025-12
Insmed USD 20.6M 217K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
J&J USD 43M 25M 2026-03
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 304M 23M 2025-12
Pfizer USD 711M 59M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 178M 203M 2026-03
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12